Shares of Terns Pharmaceuticals, a biotech company with a market capitalization of $641.8 million, surged nearly 17% on Monday, September 9. The trigger was clinical trial results showing that more than half of the patients using the highest dose of the company’s oral weight-loss drug lost 5% of their body…